Zoledronic acid treatment impairs protein geranyl-geranylation for biological effects in prostatic cells-5

<p><b>Copyright information:</b></p><p>Taken from "Zoledronic acid treatment impairs protein geranyl-geranylation for biological effects in prostatic cells"</p><p>BMC Cancer 2006;6():60-60.</p><p>Published online 15 Mar 2006</p><p>PMCID:PMC1434759.</p><p>Copyright © 2006 Goffinet et al; licensee BioMed Central Ltd.</p> to the medium for 2 hours more. Sterols were separated by thin layer chromatography (silica gel F/ethyl acetate). [C]-Cholesterol was revealed and quantified by autoradiography with Phophorimager(Molecular Dynamics)

Zoledronic acid treatment impairs protein geranyl-geranylation for biological effects in prostatic cells-1

<p><b>Copyright information:</b></p><p>Taken from "Zoledronic acid treatment impairs protein geranyl-geranylation for biological effects in prostatic cells"</p><p>BMC Cancer 2006;6():60-60.</p><p>Published online 15 Mar 2006</p><p>PMCID:PMC1434759.</p><p>Copyright © 2006 Goffinet et al; licensee BioMed Central Ltd.</p>D3, cells were treated by vehicle or 20 μM zoledronate (ZOL) in the presence or absence of intermediates of the mevalonate pathway (GGOH = geranyl-geraniol; MVA = mevalonate; FOH = farnesol; SQUA = squalene) at the indicated doses. Results are are expressed as the ratio OD/ODof three independent assays each performed six times. Error bars indicate inter-assay mean ± 1 SD. * indicates a significant difference versus ZOL-treated cells (p < 0.01). PC-3 PNT1A LNCa

Zoledronic acid treatment impairs protein geranyl-geranylation for biological effects in prostatic cells-3

<p><b>Copyright information:</b></p><p>Taken from "Zoledronic acid treatment impairs protein geranyl-geranylation for biological effects in prostatic cells"</p><p>BMC Cancer 2006;6():60-60.</p><p>Published online 15 Mar 2006</p><p>PMCID:PMC1434759.</p><p>Copyright © 2006 Goffinet et al; licensee BioMed Central Ltd.</p> (0.5 μM, 8–10 Ci/mmol) incorporation into a mutant form of H-ras with a geranyl-geranylation CAXX box. The level of prenylation is expressed as a percentage of maximum incorporation of [H]-prenyl, as determined by allowing the uninhibited reaction to go to completion. : Western-blot analysis; PC-3 cells are treated by vehicle, ZOL 20 μM; ZOL 20 μM + FOH 10 μM; ZOL 20 μM + GGOH 10 μM

Zoledronic acid treatment impairs protein geranyl-geranylation for biological effects in prostatic cells-0

<p><b>Copyright information:</b></p><p>Taken from "Zoledronic acid treatment impairs protein geranyl-geranylation for biological effects in prostatic cells"</p><p>BMC Cancer 2006;6():60-60.</p><p>Published online 15 Mar 2006</p><p>PMCID:PMC1434759.</p><p>Copyright © 2006 Goffinet et al; licensee BioMed Central Ltd.</p>nd D3, cells were treated by vehicle or increasing doses of zoledronate (ZOL: 5, 10, 15, 20 μM). At D5, the cells were fixed with TCA and stained with 0.4% sulforhodamine. Staining intensity was quantified at 540 nm. Results are expressed as the ratio OD/ODof three independent assays each performed six times. Error bars indicate inter-assay mean ± 1 SD. * indicates a significant difference versus non-treated cells (p < 0.01). PC3 PNT1A LNCa